myLifeGenome

Maximise clinical utility in genetic testing

Whole genome sequencing (WGS) is an advanced genetic analysis technique that is gaining recognition as the first line genetic test of choice in routine clinical settings [Ref ↗︎] because it goes beyond the conventional scope of targeted tests. It encompasses the coding regions, the non-coding regions as well as the mitochondrial DNA (mtDNA), which provides a comprehensive view of your patient’s genetic make-up and maximises the value.

Transform Patient Management: diagnostic genome findings can lead to tangible changes in patient management for up to 77% of patients
Shorten Diagnostic Journey: WGS offers significant potential and can end the diagnostic odyssey for 20-60% of neonates and 17-40% of pediatric patients with suspected genetic diseases.
Cost-Effective Solution: WGS as a first-line test may provide cost-effective solutions for patients suspected of rare diseases compared to alternative genetic tests
Supported by Guidelines: endorsed by the Medical Genome Initiative and incorporated into clinical practice guidelines by the ACMG and ESHG, WGS is recommended as a primary diagnostic tool for suspected rare genetic diseases

myLifeGenome

Highest clinical utility: capture the widest spectrum of variant types (SNVs, Indels, CNVs, structural variants, repeat expansion, etc.) to achieve timely diagnosis of rare diseases
Efficient turnaround time: expedite your patient’s insights with results available in no more than 20 days post-sample receipt
Re-evaluation: benefit from two follow-up analyses within 12 months, enhancing the continuous clinical utility of whole genome sequencing
Pharmacogenomics included: tailor prescriptions based on an individual’s genetic profile to enhance patient care

Who can benefit from myLifeGenome

Patients with broad, unspecific or overlapping phenotypic features that may not clearly point to a single specific disease
Individuals whose clinical manifestations are unclear or atypical, where traditional diagnostic approaches may prove insufficient in identifying the underlying cause
Cases of pediatric patients exhibiting complicated clinical features that indicate an underlying genetic disorder, a single diagnostic test can facilitate a swift diagnosis and potential treatment

Assess treatment responses with pharmacogenomics: an integral part of the myLifeGenome report

The pharmacogenomics (PGx) section includes 81 gene-drug associations. It indicates how a patient’s genetic profile influences the response to medications and can facilitate a personalized treatment plan by

optimizing drug selection and dosage
identifying patients at risk of adverse reactions
streamlining the trial-and-error process often associated with finding the right treatment

Categories of variants detected with myLifeGenome

Variant Type	Definition	myLifeGenome
Single nucleotide variants (SNVs)	A DNA sequence variant affecting 1 nucleotide	All
Insertion / Deletion (In-dels)	Deletions, insertions, or duplications of DNA segments less than 500bp	All
Copy number variants (CNVs)	Deletions or duplications of DNA segments of at least 500bp	All
Structural variants (SVs)	Insertions of DNA segments of at least 500bp, inversions and translocations (including translocations between nDNA and mtDNA)	All
Repeat expansions	Increase in the number of repeated DNA sequence motifs within a gene	Most
Chromosomal abnormalities	Monosomy, trisomy, uniparental disomy, triploidy	All

myLifeGenome Test Offering

This test was developed by Arcensus laboratory.

TAT

Up to 20 working days upon sample receipt

Library kit

Illumina TruSeq Nano DNA High throughput library prep kit

Coverage

Median coverage: 30×

Method & Platform

Next-generation sequencing: Illumina NovaSeq 6000 or NovaSeqX (Plus)

Types of Variants detected

Single-nucleotide variants, small insertions & deletions, copy number variants, repeat expansions (confirmation testing recommended), structural variants, mitochondria

Sample Types

We accept buccal swabs, blood, DBS cards, saliva and isolated DNA*

* Arcensus only accepts isolated or extracted nucleic acids for which extraction or isolation is performed in an appropriately qualified laboratory.

Contact us

We can help. Our team of experts is on hand to answer your questions.